Meconium-induced release of cytokines is mediated by the TRL4/MD-2 complex in a CD14-dependent manner

Bodil Salvesen1, Jørgen Stenvik, Carlo Rossetti

  • 1Institute of Immunology, University of Oslo and Rikshospitalet University Hospital, Oslo, Norway. bodil.salvesen@rr-research.no

Molecular Immunology
|January 23, 2010
PubMed
Abstract

Insights

Meconium triggers inflammation via the CD14-dependent TLR4/MD-2 complex. Inhibiting this pathway significantly reduces inflammatory mediators, offering therapeutic potential for meconium aspiration syndrome.

Area of Science:

  • Immunology
  • Neonatal Medicine
  • Molecular Biology

Background:

  • Meconium, the first neonatal stool, can initiate a systemic inflammatory response.
  • Toll-like receptors (TLRs) recognize molecular patterns and mediate inflammatory signaling.
  • The CD14/TLR4/MD-2 complex is implicated in recognizing various inflammatory triggers.

Purpose of the Study:

  • To investigate the role of the CD14/TLR4/MD-2 complex in meconium-induced inflammation.
  • To determine if CyP, an LPS antagonist, or anti-CD14 can inhibit meconium-induced inflammatory responses.

Main Methods:

  • Whole blood assays with anti-CD14 or CyP followed by meconium exposure.
  • Measurement of 27 inflammatory mediators using Bioplex.
  • Reporter gene assays in transfected human embryonic kidney cells to assess NF-kappaB activation.

Main Results:

  • Meconium induced a wide range of inflammatory mediators.
  • Both CyP and anti-CD14 significantly inhibited the formation of pro-inflammatory cytokines, anti-inflammatory cytokines, chemokines, and growth factors.
  • Meconium activated NF-kappaB in cells expressing TLR4/MD-2 and CD14, but not in cells lacking CD14.

Conclusions:

  • Meconium-induced inflammation is mediated through the CD14-dependent TLR4/MD-2 complex.
  • These findings suggest potential therapeutic targets for meconium aspiration syndrome.